S268: SAFETY, TOLERABILITY, AND PHARMACOKINETIC/PHARMACODYNAMIC RESULTS FROM PHASE 1 STUDIES OF GBT021601, A NEXT-GENERATION HBS POLYMERIZATION INHIBITOR FOR TREATMENT OF SICKLE CELL DISEASE

• C. Brown,
• C. Key,
• I. Agodoa,
• J. Olbertz,
• K. Duchin,
• A. Barth,
• E. Lisbon

Affiliations

C. Brown

1 Aflac Cancer and Blood Disorder Center of Children’s Healthcare of Atlanta and Department of Pediatrics, Emory School of Medicine, Atlanta

C. Key

2 ICON plc, San Antonio

I. Agodoa

3 Global Blood Therapeutics, South San Francisco, United States of America

J. Olbertz

3 Global Blood Therapeutics, South San Francisco, United States of America

K. Duchin

3 Global Blood Therapeutics, South San Francisco, United States of America

A. Barth

3 Global Blood Therapeutics, South San Francisco, United States of America

E. Lisbon

3 Global Blood Therapeutics, South San Francisco, United States of America